drugset / Trial / NCT00500344
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
NaSingle-groupOpen-labelTreatment
Summary
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
Timeline
- Start
- 2007-07
- Primary completion
- 2009-03
- Completion
- 2009-03
Publications
- Background Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004 Mar;137(3):486-95. doi: 10.1016/j.ajo.2003.11.069.
- Background van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18(9):845-54. doi: 10.1023/a:1025643303914.
- Sheybani A, Brantley MA Jr, Apte RS. Pattern electroretinography in age-related macular degeneration. Arch Ophthalmol. 2011 May;129(5):580-4. doi: 10.1001/archophthalmol.2011.83.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |